Bastiaan Driehuys
17
7
7
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
11.8%
2 terminated/withdrawn out of 17 trials
80.0%
-6.5% vs industry average
0%
0 trials in Phase 3/4
75%
6 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
Xenon MRI Pulm Hypertension
Role: lead
Oxidative Stress in Asthma
Role: lead
Pulmonary Hypertension SOLAR
Role: lead
129 Xenon Imaging in Patients Treated With Sotatercept
Role: lead
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
Role: lead
Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease
Role: lead
129Xe MRI Cardiopulmonary
Role: lead
Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
Role: lead
Downstream Effects of Airway Mucus Plugs on 129Xenon MRI in Severe Asthma
Role: lead
Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia
Role: lead
Dual MRI for Cardiopulmonary COVID-19 Long Haulers
Role: lead
Xenon MRI in Stable Pulmonary Hypertension (Jupiter AUGEAN)
Role: lead
Assessing Response to Inhaled Prostacyclin With Hyperpolarized Xe MRI
Role: lead
Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment
Role: lead
Non-Invasive Diagnosis of Pulmonary Vascular Disease Using Inhaled 129Xe Magnetic Resonance Imaging
Role: lead
Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis
Role: lead
Effects of Bevespi on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI
Role: lead
All 17 trials loaded